je.st
news
Tag: cancer
Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
2015-01-13 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA (pembrolizumab) with Alimta (pemetrexed), Cyramza (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LLY Exchange: NYSE read more
Tags: enter
research
agreement
types
Merck seeks new OK for cancer drug, reorganization on track
2015-01-12 20:17:01| Biotech - Topix.net
Drugmaker Merck & Co. is ratcheting up its race with rival Bristol-Myers Squibb for leadership in the hot new field of immuno-oncology.
Tanger Outlets Rehoboth donates to fight breast cancer
2015-01-10 15:47:12| Real Estate - Topix.net
Showing off the Tanger donation check are Sue Ryan of the Delaware Breast Cancer Coalition; Amy Norgate, Tanger Outlet Center general manager; and Connie Holdridge of DBCC. The Tanger Outlet Center in Rehoboth Beach raised and donated over $29,000 for the battle against breast cancer this fall.
Tags: fight
cancer
breast
outlets
Pfizer, FDA in talks on prescription details for key breast cancer drug
2015-01-08 18:21:28| Biotech - Topix.net
Pfizer Inc said Thursday it has begun talks with the U.S. Food and Drug Administration to finalize the prescription label of its breast cancer drug palbociclib, in an indication the drug was likely closer to regulatory approval. The largest U.S. drugmaker also said there was no plan for the agency to hold an advisory committee meeting to discuss the medicine prior to an approval decision.
RPT-INTERVIEW-Halozyme CEO sees blockbuster potential in its cancer drug
2015-01-08 16:16:25| Biotech - Topix.net
The drug, PEGPH20, being tested against pancreatic cancer, has the potential to help treat several other types of solid tumor cancers, its chief executive said in an interview. Halozyme discussed interim data from a Phase II study of PEGPH20 with analysts and investors in New York on Wednesday, demonstrating its likelihood of delaying a worsening of the deadly cancer.
Tags: potential
drug
cancer
ceo
Sites : [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] next »